Merck Q1 2023 Report Shows Revenue Drop as COVID Treatment Sales Crash, MRK Stock Down 1%
Affected by reduced demand for Covid drug Molnupiravir, Merck has published reduced revenue figures according to its Q1 2023 report. Multinational pharmaceutical giant Merck & Co Inc (NYSE: MRK) has released its Q1 2023 report. The company’s figures show a reduction in revenue due to several factors, including a plunge in
Read More